Do we need more nucleos(t)ide analogs for the treatment of chronic hepatitis B?

Affiliations

Free article

Editorial

Jorg Petersen. J Hepatol. 2015 Mar.

Free article

. 2015 Mar;62(3):505-7.

doi: 10.1016/j.jhep.2014.12.003. Epub 2014 Dec 10.

¹ IFI Institute at the Asklepios Klinik St Georg Hamburg, University of Hamburg, Germany. Electronic address: petersen@ifi-medizin.de.

No abstract available

Comment on

Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study.
Yuen MF, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee JW, Park NH, Kweon YO, Sohn JH, Lee J, Kim JA, Lai CL, Han KH. Yuen MF, et al. J Hepatol. 2015 Mar;62(3):526-32. doi: 10.1016/j.jhep.2014.10.026. Epub 2014 Oct 25. J Hepatol. 2015. PMID: 25450709 Clinical Trial.
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.
Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E, Zhao S, Subramanian GM, McHutchison JG, Gane EJ, Foster GR. Agarwal K, et al. J Hepatol. 2015 Mar;62(3):533-40. doi: 10.1016/j.jhep.2014.10.035. Epub 2014 Oct 30. J Hepatol. 2015. PMID: 25450717 Clinical Trial.